Furthermore, synergistic effects of PD-1/PD-L1 inhibitors and chemotherapy or BV have been observed in newly diagnosed or R/R CHL patients, respectively, indicating that PD-1/PD-L1 blockade in combination with other therapeutic agents may be a future strategy. Here, CD274 is linked to classic Hodgkin lymphoma.